Monoclonal antibody UJ13A

Drug Profile

Monoclonal antibody UJ13A

Latest Information Update: 14 Jul 1998

Price : $50

At a glance

  • Originator Imperial Cancer Research Technology
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Glioma

Most Recent Events

  • 14 Jul 1998 No-Development-Reported for Glioma in United Kingdom (Unknown route)
  • 02 Feb 1995 Phase-I clinical trials for Glioma in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top